Corvidia
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
35 Gatehouse Dr, Waltham, Massachusetts,...Phone Number
(781) 205-4755Website
www.corvidiatx.comRevenue
$12.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Corvidia
Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis. Founded in 2015, Corvidia Therapeutics is headquartered in Waltham, Massachusetts.Explore more
Corvidia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Corvidia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Corvidia is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Corvidia
Funding: Get notified immidiatlly once Corvidia has new funding data
Earning: See what the market has to say on Corvidia recently announced quarterly report
Product Launch: Get notified when Corvidia launches new products
Click to see if Corvidia had a recent Job posting/layoffs
Corvidia, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Corvidia has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Corvidia as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Corvidia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Corvidia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Corvidia.
Corvidia financials insights
Gather financial insights about Corvidia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$26M
2018
Series B
$60M
Corvidia Tech Stack
Most Recent Scoops
Left Company
Executive Move
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Gaozhong Zhu, Vice President & Head of Pharmaceutical Development & Manufacturing, has left the company.
Executive Move
Executive Moves, Board of Directors
Mergers & Acquisitions (M&A)
Corvidia News & Media
Novo Nordisk To Buy Corvidia Therapeutics For Up To $2.1B
Novo Nordisk will pay $725 million upfront, and total payments could be up to $2.1 billion, so long as certain regulatory and sales milestones are reached.Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia
Diabetes drug giant Novo Nordisk has reached a $725 million deal to acquire Corvidia Therapeutics, a clinical-stage biotech developing treatments for disorders affecting the heart and the kidneys. The upfront payment due to Corvidia shareholders is cash. According to the terms of the agreement, Denmark-based Novo Nordisk (NASDAQ: NOVO) could be on the hook for […]Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk
PARIS--(BUSINESS WIRE)-- #investing--Sofinnova Partners announces sale of Corvidia Therapeutics to Novo Nordisk for $2.1B
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Corvidia
Sign Up For FreeTo access detailed company insights
Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pan... Read More
